Abstract Search

ea0049gp231 | Thyroid Cancer | ECE2017

Management and outcome of bone metastasis from differentiated thyroid carcinoma in the real life: the M.OS.CA.TI. study

Mazziotti Gherardo , Panarotto Maria Beatrice , Arvat Emanuela , Chiti Arturo , Cuocolo Alberto , Dottorini Massimo , Elisei Rossella , Filetti Sebastiano , Filice Angelina , Formenti Anna Maria , Pace Leonardo , Pellegrino Teresa , Nodari Marcello , Salvatori Massimo , Tranfaglia Cristina , Versari Annibale , Frara Stefano , Berruti Alfredo , Giustina Andrea , Giubbini Raffaele

Although differentiated thyroid cancer (DTC) has the third highest propensity to spread to the bone after breast and prostate cancer, there is a paucity of data concerning the treatment of bone metastasis (BM) in this setting. The MOSCATI (Metastasi OSsee da Carcinoma TIroideo) was a multicenter, retrospective study investigating the real-life outcome and management of BM in 143 patients (80 F, 63 M; median age 60 years) with DTC involving 10 specialized cente...

0 shares

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...

0 shares

Endocrine Abstracts

Management and outcome of bone metastasis from differentiated thyroid carcinoma in the real life: the M.OS.CA.TI. study

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

BiosciAbstracts